Valuation: Gilead Sciences, Inc.

Market Cap 169B 148B 137B 126B 239B 16,147B 244B 1,642B 638B 7,902B 633B 619B 27,430B P/E 2026 *
-48.1x
P/E 2027 * 17.6x
Enterprise Value 178B 156B 144B 133B 253B 17,052B 258B 1,734B 674B 8,345B 669B 654B 28,968B EV / Sales 2026 *
5.84x
EV / Sales 2027 * 5.21x
Free-Float
99.88%
Yield 2026 *
2.39%
Yield 2027 * 2.48%
1 day-0.82%
1 week+4.11%
Current month+7.41%
1 month+8.37%
3 months-2.07%
6 months+15.30%
Current year+12.70%
1 week 112.82
Extreme 112.82
121
1 month 105.24
Extreme 105.24
121
Current year 100.42
Extreme 100.42
132
1 year 92.46
Extreme 92.46
132
3 years 57.58
Extreme 57.58
132
5 years 52.23
Extreme 52.23
132
10 years 46.23
Extreme 46.23
132
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+4.11% - - 169B
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-0.40%-2.11%+28.58%+26.03% 330B
-8.67%-10.19%+26.00%+28.25% 295B
-0.81%-2.33%+28.18%+45.77% 285B
-0.80%-3.33%-27.56%-39.55% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.08%+0.71%-6.13%-32.31% 137B
Average -1.54%+1.73%+25.73%+46.37% 403.15B
Weighted average by Cap. -1.64%+2.16%+39.34%+80.96%

Financials

2026 *2027 *
Net sales 30.47B 26.72B 24.67B 22.8B 43.21B 2,917B 44.08B 297B 115B 1,428B 114B 112B 4,956B 32.38B 28.4B 26.22B 24.23B 45.92B 3,100B 46.84B 315B 122B 1,517B 122B 119B 5,266B
Net income -3.37B -2.96B -2.73B -2.52B -4.78B -323B -4.88B -32.83B -12.76B -158B -12.67B -12.39B -549B 9.55B 8.37B 7.73B 7.14B 13.54B 914B 13.81B 92.95B 36.12B 447B 35.86B 35.07B 1,553B
Net Debt 9.46B 8.3B 7.66B 7.08B 13.42B 906B 13.69B 92.09B 35.78B 443B 35.53B 34.75B 1,539B -96.43M -84.58M -78.09M -72.16M -137M -9.23B -140M -939M -365M -4.52B -362M -354M -15.69B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
09/07/26 EUR 119.08 -0.03% 8
08/07/26 EUR 119.12 +1.38% 321
07/07/26 EUR 117.50 +4.15% 57
06/07/26 EUR 112.82 -1.79% 351
03/07/26 EUR 114.88 +0.44% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.82USD
Average target price
158.30USD
Spread / Average Target
+16.55%

Quarterly revenue - Rate of surprise